4-((2-羟基乙基)氨基)哌啶-1-羧酸叔丁酯 | 701298-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-((2-羟基乙基)氨基)哌啶-1-羧酸叔丁酯
• 英文名称: tert-butyl 4-[(2-hydroxyethyl)amino]piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(2-hydroxyethylamino)piperidine-1-carboxylate；4-(2-hydroxyethylamino)piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-((2-hydroxyethyl)amino)piperidine-1-carboxylate；tert-butyl 4-(2-hydroxyethyl)amino-1-piperidinecarboxylate
• CAS: 701298-37-5
• 化学式: C₁₂H₂₄N₂O₃
• 分子量: 244.334
• InChiKey: XFSNCFDIVKNIKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((2-羟基乙基)氨基)哌啶-1-羧酸叔丁酯 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-[(4-Fluoro-2-trifluoromethyl-benzyl)-piperidin-4-yl-amino]-ethanol
  参考文献：
  名称：

  N-Alkyl-N-arylmethylpiperidin-4-amines: Novel dual inhibitors of serotonin and norepinephrine reuptake

  摘要：

  A series of N-alkyl-N-arylmethylpiperidin-4-amines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.008
• 作为产物：
  描述：

  在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 15.0h， 生成 4-((2-羟基乙基)氨基)哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  EP1564213

  摘要：

  公开号：

文献信息

• Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2
  作者：Sanjita Sasmal、D. Balasubrahmanyam、Hariprasada R. Kanna Reddy、Gade Balaji、Gujjary Srinivas、Srisailam Cheera、Chandrasekhar Abbineni、Pradip K. Sasmal、Ish Khanna、V.J. Sebastian、Vikram P. Jadhav、Manvendra P. Singh、Rashmi Talwar、J. Suresh、Dhanya Shashikumar、K. Harinder Reddy、V. Sihorkar、Thomas M. Frimurer、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2012.03.049

  日期：2012.5

  Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in

  黑色素浓缩激素受体 1 (MCHR1) 拮抗剂具有治疗肥胖和多种中枢神经系统疾病的潜力。在上一篇文章中，我们描述了一系列新型喹唑啉作为 MCHR1 拮抗剂，并通过早期先导证明了体内原理证明。在此，我们描述了详细的 SAR 和 SPR 研究，以确定在亚慢性 DIO 模型中具有良好疗效且具有良好心血管安全窗口的优化先导候选药物。
• INHIBITORS OF SPHINGOSINE KINASE
  申请人：Stieber Frank

  公开号：US20120252789A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , M 1 , M 2 , M 3 , M 4 , Y 1 , Y 2 , V, W, n, m and o have the meanings given in Claim 1 , and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、M1、M2、M3、M4、Y1、Y2、V、W、n、m和o具有权利要求1中给出的含义，以及其生理上可接受的盐、衍生物、前药、溶剂合物、互变异构体和立体异构体，包括所有比例的混合物，用于治疗受Sph激酶1抑制影响的疾病。
• [EN] GAS CAPTURE PROCESS<br/>[FR] PROCÉDÉ DE CAPTURE DE GAZ
  申请人：COMMW SCIENT IND RES ORG

  公开号：WO2012142668A1

  公开（公告）日：2012-10-26

  A process for the capture of CO2 from gas streams, the process including contacting a CO2 containing gas stream with a compound including: a primary or non-sterically hindered secondary amine group and at least one tertiary amine or sterically hindered secondary amine group; wherein the primary or non-sterically hindered secondary amine and the nearest tertiary or sterically hindered secondary amine group are separated by a carbon chain including 3 or 4 carbon atoms and wherein the compound is a compound of Formula (I).

  一种从气体流中捕获CO2的过程，该过程包括将含CO2的气体流与一种化合物接触，该化合物包括：一个主要或非立体位阻的次级胺基团和至少一个三级胺基或立体位阻的次级胺基团；其中主要或非立体位阻的次级胺和最近的三级或立体位阻的次级胺基团之间由包括3或4个碳原子的碳链分隔，且该化合物是Formula (I)的化合物。
• Urea derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070093501A1

  公开（公告）日：2007-04-26

  The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R 1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O) 2 —; W is —N(R 2 )—, —O—, or a bond (wherein R 2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O) 2 —; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] , are each independently a single bond or a double bond; provided that R 1 may be bonded to R 2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R 2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

  本发明提供一种尿素衍生物或其盐，其作为治疗血栓症的治疗剂是有用的。该衍生物由公式（I）表示：其中，Cy是芳香族羟基烃基或芳香族杂环基，可以被取代；R1是氢原子或可以被取代的碳氢基团；V是-C（O）-，-S（O）-或-S（O）2-；W是-N（R2）-，-O-或键（其中R2是氢原子或可以被取代的碳氢基团）；X是可以被取代的烷基；Y是-C（O）-，-S（O）-或-S（O）2-；Z是键，可以被取代的链烃基团或-N═；环A是非芳香族含氮杂环环，可以被取代；环B是含氮杂环环，可以被取代；而[化学式2]都是单键或双键；但是，R1可以与R2连接形成非芳香族含氮杂环环，而R2可以与X的取代基连接形成可以被取代的非芳香族含氮杂环环。
• Imidazole derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070004736A1

  公开（公告）日：2007-01-04

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O) 2 — or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z 1 and Z 3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z 2 represents —N(R 1 )—, —O—, —S(O)—, —S(O) 2 —, —CO—, —CH(R 1 )— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R 1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，用作治疗血栓的药物，其化学式表示为(I)式：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价直链烃基，X代表可选取代的二价烃基，Y代表-CO-、-S(O)-、-S(O)2-或键，环A代表可选取代的吡咯烷环、可选取代的哌啶环或可选取代的过氢杂环己烷环，Z1和Z3独立地代表键或可选取代的二价直链烃基，Z2代表-N(R1)-、-O-、-S(O)-、-S(O)2-、-CO-、-CH(R1)-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所具有的取代基可以与R1一起形成可选取代的环，a代表0、1或2。